利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

131 条记录 (耗时 0.03 秒)

    USE OF CANNABINOIDS IN THE TREATMENT OF MENTAL DISORDERS
    3.
    发明公开
    USE OF CANNABINOIDS IN THE TREATMENT OF MENTAL DISORDERS 审中-公开

    公开(公告)号：EP3346999A1

    公开(公告)日：2018-07-18

    申请号：EP16766051.3

    申请日：2016-09-08

    申请人： GW Pharma Limited

    发明人： ROBSON, Philip ,  GUY, Geoffrey ,  WRIGHT, Stephen ,  CHEETHAM, Emma ,  SCHILLER, Dominic

    IPC分类号： A61K31/05 ,  A61K31/496 ,  A61P25/18

    CPC分类号： A61K31/05 ,  A61K31/40 ,  A61K31/496 ,  A61K31/519 ,  A61K31/551 ,  A61K31/5513 ,  A61K31/554 ,  A61P25/18 ,  A61K2300/00

    摘要： This invention relates to the use of CBD to treat mental disorders. For example it can be used as an adjunct therapy to treat positive symptoms in mental disorders such as schizophrenia and related disorders; or as an adjunct therapy in combination with olanzapine to treat both positive and negative symptoms in mental disorders such as schizophrenia and related disorders; or as an adjunct therapy in combination with olanzapine to treat negative symptoms in mental disorders such as schizophrenia and related disorders; or as an adjunct therapy to treat anhedonia/asociality in mental disorders such as schizophrenia and related disorders; or as an adjunct therapy to treat avolition/apathy in mental disorders such as schizophrenia and related disorders; or as an adjunct therapy to treat disturbance of attention in mental disorders such as schizophrenia and related disorders; or as a monotherapy or as an adjunct therapy to treat one or more distinct sub-domains of negative symptoms selected from: i) avolition/apathy; ii) anhedonia/asociality and iii) disturbance of attention; or as an adjunct therapy to treat cognitive symptoms, particularly working memory, motor speed and executive function in mental disorders such as schizophrenia and related disorders. There may additionally be provided compositions comprising CBD in combination with one or more antipsychotics such as olanzapine and quetiapine. In particular the invention relates to the treatment of schizophrenia or related psychotic disorders, more particularly still those which are considered to be treatment resistant.

    7-OH-CANNABIDIOL (7-OH-CBD) AND/OR 7-OH-CANNABIDIVARIN (7-OH-CBDV) FOR USE IN THE TREATMENT OF EPILEPSY
    4.
    发明公开
    7-OH-CANNABIDIOL (7-OH-CBD) AND/OR 7-OH-CANNABIDIVARIN (7-OH-CBDV) FOR USE IN THE TREATMENT OF EPILEPSY 审中-公开
    用于治疗癫痫的7-OH-大麻二酚（7-OH-CBD）和/或7-OH-大麻二肽（7-OH-CBDV）

    公开(公告)号：EP3160457A1

    公开(公告)日：2017-05-03

    申请号：EP15733514.2

    申请日：2015-06-29

    申请人： GW Pharma Limited

    发明人： STOTT, Colin ,  JONES, Nick ,  WHALLEY, Benjamin ,  STEPHENS, Gary ,  WILLIAMS, Claire

    IPC分类号： A61K31/05 ,  A61P25/08

    摘要： The present invention relates to the use of 7-hydroxy-cannabidol (7-OH-CBD) and/or 7-hydroxy-cannabidivarin (7-OH-CBDV) in the treatment of epilepsy. Preferably the cannabinoid metabolites are isolated from plants to produce a highly purified extract or can be reproduced synthetically.

    摘要翻译： 提供了用作药物，特别是治疗癫痫症的7-羟基 - 大麻双胍（7-OH-CBDV）。 还提供了用于治疗癫痫症的7-羟基 - 大麻二酚（7-OH-CBD）。 7-OH-CBDV和7-OH-CBD可以组合使用用于治疗癫痫。 7-OH-CBDV和/或7-OH-CBD可以与一种或多种优选选自clobazam，左乙拉西坦，托吡酯，stiripentol，苯巴比妥，lacsamide， 丙戊酸，唑尼沙胺，龙柏酸和磷苯妥英。 优选7-OH-CBD和/或7-OH-CBDV的剂量在1和2000mg / kg之间。 当7-OH-CBD与7-OH-CBDV组合使用时，7-OH-CBD可以配制成与7-OH-CBDV分开，依次或同时给药，或者可以以 单剂量形式。

    7-HYDROXY CANNABIDIOL (7-OH-CBD) FOR USE IN THE TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD)
    5.
    发明公开
    7-HYDROXY CANNABIDIOL (7-OH-CBD) FOR USE IN THE TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) 审中-公开
    7-羟基大麻二酚（7-OH-CBD）用于治疗非酒精性脂肪肝（NAFLD）

    公开(公告)号：EP3160456A1

    公开(公告)日：2017-05-03

    申请号：EP15733513.4

    申请日：2015-06-29

    申请人： GW Pharma Limited

    发明人： STOTT, Colin ,  DUNCAN, Marnie ,  DI MARZO, Vincenzo ,  SILVESTRI, Cristoforo ,  MARTELLA, Andrea

    IPC分类号： A61K31/05 ,  A61P1/16

    CPC分类号： A61K31/05

    摘要： The liver plays a key role in regulating total body energy homeostasis and its ability to do so is greatly affected by the occurrence of pathological conditions such as hepatosteatosis or non-alcoholic fatty liver disease (NAFLD), which contributes to hepatic insulin resistance and potentially end-stage liver disease-related mortality. Triglyceride accumulation in hepatocytes of steatotic livers results from the incorporation of plasma free fatty acids as well as de novo fat synthesis. The present invention relates to the use of 7-hydroxy-cannabidiol (7-OH-CBD) in the treatment of non-alcoholic fatty liver disease (NAFLD). Treatment of NAFLD involves lowering the triglyceride levels in a patient's blood stream.

    摘要翻译： 肝脏在调节全身能量平衡方面起着关键作用，其发生能力受到肝脏脂肪变性或非酒精性脂肪肝病（NAFLD）等病理状况的严重影响，这些病理状态有助于肝脏胰岛素抵抗并可能终止 阶段肝病相关死亡率。 甘油三酯在脂肪肝的肝细胞中的积累是由于掺入了血浆游离脂肪酸以及从头脂肪合成。 本发明提供用于治疗非酒精性脂肪肝病（NAFLD）的7-羟基 - 大麻二酚（7-OH-CBD）。 优选地，治疗涉及降低患者血流中的甘油三酯水平，其中高甘油三酯水平可能由肥胖症，II型糖尿病或药物引起。 7-OH-CBD的剂量优选在1和1000mg / kg天之间。 概述了包含7-OH-CBD和一种或多种赋形剂的药物制剂，其中7-OH-CBD可以与另一种药物分开，依次或同时使用或在单一剂型内提供。